As a CEO of OncoSec Medical Incorporated, developed and executed a more focused and realistic strategy for development of TAVO™-EP that resulted in FDA buy-in for clinical path forward and closed two Nasdaq funding rounds and one round of undiluted funding during organizational restructuring.Flexible and dynamic leader who introduced cultural changes and team transformation of Elpiscience R&D approach in a growing company during transition from 39 to 120 employees with successful in-licensing of assets and stage-up of two assets for clinical starts.Ability to visualize and articulate both long-term and near-term goals while promoting excellence through organization design, leverage of key functional areas, with clear decision making and process application during execution; identified and advanced multiple first-in-class and best-in-disease assets from pre-clinical to clinical PhIII programs.Solid foundation in immunology and liver disease. With hands-on experience in small molecules and biologics, such as gene therapy and (Ab) therapeutics from idea to clinical studies of monoclonal Abs to bi-specifics and conjugates with delivery from program idea to PhII including internal and external fund raising in academia, pharma and biotech (private, NIH, VC, Nasdaq) setting.